CVS Health Reports Strong Q2 2026 Results and Raises Full-Year Guidance

Details

The company reported GAAP diluted EPS of $2.31 and Adjusted EPS of $2.58. CVS Health also raised its full-year 2026 guidance, with GAAP diluted EPS guidance now ranging from $6.84 to $7.04 and Adjusted EPS guidance ranging from $7.90 to $8.10. The company attributed the strong performance to growth across all operating segments and improved operating income, particularly in the Health Care Benefits segment.

Items reported

About CVS Health Corporation

CVS Health Corporation is a leading health services company in the United States, offering a comprehensive range of services aimed at improving healthcare accessibility and convenience. Primarily known for its extensive network of pharmacies, CVS Health operates thousands of retail locations nationwide. These outlets provide prescription medications, over-the-counter drugs, health and wellness products, and immunization services. Beyond retail, CVS Health plays a significant role in the healthcare sector through its pharmacy benefit management division, Caremark, which administers prescription drug plans for insurers and employers. Additionally, the company owns Aetna, a major health insurance provider, aligning its services across retail, pharmacy benefits, and insurance solutions to deliver integrated healthcare experiences. With its broad reach and diverse healthcare offerings, CVS Health Corporation holds a critical place in the healthcare market, continuously working to streamline and enhance the delivery of medical services across the country.